Novo Nordisk A/S (NVO) - Episode 130 - Nov 5, 2025

📉 Which Story Do You Trust: The Blockbuster Fundamentals or the Bearish Chart? 📈 On this episode of D-Risk, we dive deep into pharmaceutical titan Novo Nordisk, a company fundamentally firing on all cylinders with a 12% sales surge from its blockbuster drugs and a massive $10 billion-plus M&A push to dominate the weight-loss market. Analysts are overwhelmingly bullish, and our valuation suggests the stock is significantly undervalued. But here's the conflict: the stock chart is a disaster, flashing dark red with long-term trend, volume, and momentum indicators pointing sharply down. The question isn't whether the company is healthy, but whether its phenomenal success can finally stop the relentless selling pressure and rewrite a truly ugly technical narrative. Tune in to get our full strategic outlook and find out where we see the critical lines in the sand.